Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

PLUS THERAPEUTICS, INC. Director's Dealing 2023

Feb 17, 2023

34301_dirs_2023-02-17_68104abc-5ad9-46b9-8d8c-51797cc56835.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: PLUS THERAPEUTICS, INC. (PSTV)
CIK: 0001095981
Period of Report: 2023-02-15

Reporting Person: LaFrance Norman D. (Chief Medical Officer)

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2023-02-15 Stock Option (Right to Buy) $0.39 A 74981 Acquired 2033-02-15 Common Stock (74981) Direct

Footnotes

F1: The options vest over four years in equal 1/48th increments on each monthly anniversary of the issuance.